INVESTORS
NEWSROOM
Responsibility
SUBSCRIBE
CONSUMERS
HEALTHCARE PROFESSIONALS
CAREERS
ABOUT ABBOTT
Small Tech, Big Impact
New data reinforce Abbott’s leadership in minimally invasive structural heart therapies.
Abbott has rolled out a slew of new data on five of its life-changing structural heart technologies, including the MitraClip system (repairs a leaky mitral valve) the Amplatzer Amulet LAA Occluder* (designed to help reduce stroke risk in people with atrial fibrillation) and the PorticoTM with FlexNavTM transcatheter aortic valve replacement system* (replaces a diseased or damaged aortic valve).
Get the details on these findings, which reinforce Abbott’s position as a leader in minimally invasive structural heart treatments.
*These products are available commercially in the EU and are in clinical trials in the United States.
INFORMATION AND SAFETY INFORMATION
INDICATION FOR USE
CONTRAINDICATIONS
The MitraClip G4 System is contraindicated in patients with the following conditions:
WARNINGS
PRECAUTIONS
Secondary Mitral Regurgitation
POTENTIAL COMPLICATIONS AND ADVERSE EVENTS
The following ANTICIPATED EVENTS have been identified as possible complications of the MitraClip G4 procedure.